To evaluate more in detail the effect of the combinations of IACS-010759 with the FLT3 inhibitors, we included in our screen a larger panel of both FLT3-wild-type and mutant AML cell lines (U937, OCI-AML2, OCI-AML3, MOLM-13, and MOLM-14) than in our initial screen. Here, RUNX2 is linked to acute myeloid leukemia.